Cargando…

BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition

While several systemic therapies are approved for cutaneous T cell lymphoma (CTCL), a non-Hodgkin lymphoma of skin-homing T cells that may involve lymph nodes and peripheral blood in advanced stages, relapses are common. Mutational analysis of CTCL cells has revealed frequent amplification of the MY...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Sa Rang, Lewis, Julia M., Cyrenne, Benoit M., Monico, Patrick F., Mirza, Fatima N., Carlson, Kacie R., Foss, Francine M., Girardi, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044378/ https://www.ncbi.nlm.nih.gov/pubmed/30018745 http://dx.doi.org/10.18632/oncotarget.25670

Ejemplares similares

B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma
por: King, Amber Loren O., et al.
Publicado: (2020)

Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines
por: Hölscher, Alexander S., et al.
Publicado: (2018)

FISH Panel for Leukemic Cutaneous T-Cell Lymphoma: Extended Patient Cohort Correlation with Blood Involvement and Clinical Outcomes
por: Avery, Jonathan, et al.
Publicado: (2023)

Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy
por: Manzotti, Gloria, et al.
Publicado: (2019)

Combination BET Family Protein and HDAC Inhibition Synergistically Elicits Chondrosarcoma Cell Apoptosis Through RAD51-Related DNA Damage Repair
por: Huan, Songwei, et al.
Publicado: (2020)

BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models
por: Wyce, Anastasia, et al.
Publicado: (2013)

Selective inhibition of BET bromodomains
por: Filippakopoulos, Panagis, et al.
Publicado: (2010)

Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling
por: Heinemann, Anja, et al.
Publicado: (2015)

P1280: TARGETED INHIBITION OF DHODH IS SYNERGISTIC WITH BCL2 BLOCKADE IN LYMPHOMA WITH CONCURRENT MYC AND BCL2 REARRANGEMENT
por: Mo, W., et al.
Publicado: (2022)

Investigating the Synergistic Potential of Low-Dose HDAC3 Inhibition and Radiotherapy in Alzheimer’s Disease Models
por: Ricciardi, Natalie R., et al.
Publicado: (2023)

Integrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populations
por: Ren, Jingjing, et al.
Publicado: (2022)

BET Inhibition Improves NASH and Liver Fibrosis
por: Middleton, Sarah A., et al.
Publicado: (2018)

BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer
por: Lui, Goldie Y.L., et al.
Publicado: (2020)

Bromodomain and Extraterminal (BET) Protein Inhibition Restores Redox Balance and Inhibits Myofibroblast Activation
por: Stock, Carmel J. W., et al.
Publicado: (2019)

Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions
por: Wu, Tingyu, et al.
Publicado: (2018)

The Synergistic Effect of Proanthocyanidin and HDAC Inhibitor Inhibit Breast Cancer Cell Growth and Promote Apoptosis
por: Wang, Tsz Ki, et al.
Publicado: (2023)

BET bromodomain inhibition suppresses T(H)17-mediated pathology
por: Mele, Deanna A., et al.
Publicado: (2013)

Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia
por: Brinton, Lindsey T., et al.
Publicado: (2020)

BET Inhibition Upregulates SIRT1 and Alleviates Inflammatory Responses
por: Kokkola, Tarja, et al.
Publicado: (2015)

Selective inhibition of HDAC6 sensitizes cutaneous T-cell lymphoma to PI3K inhibitors
por: Bobrowicz, Malgorzata, et al.
Publicado: (2020)

Selective BET bromodomain inhibition as an antifungal therapeutic strategy
por: Mietton, Flore, et al.
Publicado: (2017)

Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
por: Mao, Wendy, et al.
Publicado: (2019)

Inhibition and Mechanism of HDAC8 Revisited
por: Chen, Kai, et al.
Publicado: (2014)

The dark side of HDAC inhibition in ALS
por: Boutillier, Anne-Laurence, et al.
Publicado: (2019)

Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells
por: Cortiguera, María G., et al.
Publicado: (2019)

Evaluation of the Synergistic Potential of Simultaneous Pan- or Isoform-Specific BET and SYK Inhibition in B-Cell Lymphoma: An In Vitro Approach
por: Sender, Sina, et al.
Publicado: (2022)

Simultaneous Inhibition of Mcl-1 and Bcl-2 Induces Synergistic Cell Death in Hepatocellular Carcinoma
por: Michalski, Marlen, et al.
Publicado: (2023)

Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma()()
por: Zhao, Lei, et al.
Publicado: (2018)

Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma
por: Heijkants, Renier, et al.
Publicado: (2017)

BET bromodomain protein inhibition is a therapeutic option for medulloblastoma
por: Henssen, Anton, et al.
Publicado: (2013)

Autoimmune disease-associated gene expression is reduced by BET-inhibition
por: Peeters, Janneke G.C., et al.
Publicado: (2015)

BET inhibition as a new strategy for the treatment of gastric cancer
por: Montenegro, Raquel C., et al.
Publicado: (2016)

BET inhibition disrupts transcription but retains enhancer-promoter contact
por: Crump, Nicholas T., et al.
Publicado: (2021)

MEDB-85. Transcriptional complexes as resistance drivers to BET inhibition
por: Boynton, Adam, et al.
Publicado: (2022)

Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition
por: Graziani, Vittoria, et al.
Publicado: (2023)

Vascular histone deacetylation by pharmacological HDAC inhibition
por: Rafehi, Haloom, et al.
Publicado: (2014)

HDAC/IKK inhibition therapies in solid tumors
por: Vancurova, Ivana, et al.
Publicado: (2017)

HDAC Inhibition to Prime Immune Checkpoint Inhibitors
por: Borcoman, Edith, et al.
Publicado: (2021)

Hydroxygenkwanin Inhibits Class I HDAC Expression and Synergistically Enhances the Antitumor Activity of Sorafenib in Liver Cancer Cells
por: Chen, Chi-Yuan, et al.
Publicado: (2020)

JAK/BCL2 inhibition acts synergistically with LSD1 inhibitors to selectively target ETP-ALL
por: Benyoucef, Aissa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ljjnagaqkj85o462f9huakjsng